RecruitingEarly Phase 1NCT07530380

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia

A Clinical Study of CD19/BCMA-Targeted Universal Allogeneic CAR-T Cell Therapy in Relapsed/Refractory Autoimmune Hemolytic Anima: Evaluating Safety and Preliminary Efficacy

Sponsor

The Second Hospital of Anhui Medical University

Enrollment

15 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

AIHA - Warm Autoimmune Hemolytic Anemia UCART

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy

Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called QT-219C Cell Injection for people with aiha - warm autoimmune hemolytic anemia and ucart. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.